ARMATA PHARMACEUTICALS INC ARMP 深 滬
等待開盤 08-15 09:30:00 美东时间
2.53
+0.030
+1.20%
華盛通- 最 高2.53
- 今 開2.4369
- 成交量 3877股
- 最 低 2.39
- 昨 收 2.50
- 總市值 9156.96万
- 52周最高 2.96
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 0.8981
- 委 比 0.00%
- 總股本 3619.35万
- 歷史最高 10.48
- 量 比 0.41
- 振 幅 5.60%
- 歷史最低 0.8311
- 每 手 1
- 風險率 0.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Armata Pharmaceuticals Files For Mixed Shelf Of Up To $100M
https://www.sec.gov/Archives/edgar/data/921114/000110465925077648/tm2523066d1_s3.htm
08-14 05:20
Armata Pharmaceuticals Q2 EPS $(0.45) Misses $(0.39) Estimate, Sales $2.169M Beat $1.380M Estimate
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.39) by 15.38 percent. This is a 80 percent decrease over losses of $(0.25) per share
08-13 04:32
美股机会日报丨大摩喊话超配美股！中概股业绩“大丰收”，百度、文远知行盘前齐涨
中概股业绩“大丰收”！百度、文远知行、爱奇艺盘前齐涨；大摩喊话超配美股：标普500指数将升至6500点；“木头姐”连续两日加仓台积电>>
05-21 20:14
美股大行评级 | 潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
潜在涨幅300.0%！HC Wainwright & Co.：Armata Pharmaceuticals获机构升目标价至9美元，维持"买入"评级
05-21 16:44
美股大行评级 | 摩根大通：维持网易"超配"评级，目标价升至135美元；瑞银上调达美航空评级至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1131517965561573377.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Armata Pharmaceuticals(ARMP)"买入"评级，目标价从7美元升至9美元</p> <p>• 瑞银：维持爱芬奇(ANF)"买入"评级，目标价从115美
05-20 09:28
Armata Pharmaceuticals shares are trading after the comapny announced topline results from its Phase 1b/2a diSArm trial which evaluated AP-SA02, a novel intravenous administered multi-phage therapeutic for the treatment of Staphylococcus aureus bacteremia, in the intent-to-treat population.
Armata Pharmaceuticals shares are trading after the comapny announced topline r...
05-20 00:53
Armata Pharmaceuticals Q1 EPS $(0.20) Beats $(0.38) Estimate, Sales $491.00K Miss $1.38M Estimate
Armata Pharmaceuticals (AMEX:ARMP) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.38) by 47.37 percent. This is a 71.01 percent increase over losses of $(0.69) per share
05-15 04:23
H.C. Wainwright Remains a Buy on Armata Pharmaceuticals (ARMP)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Armata Phar...
05-01 22:15
Armata Pharmaceuticals Secures $10M Loan for Clinical Trials
Armata Pharmaceuticals ( ($ARMP) ) has provided an update. On March 12, 2025, A...
03-13 05:28
美股大行评级 | 潜在升幅247%，Innoviz获机构上调目标价至4美元
<span> <meta content="no-referrer" name="referrer"></span><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Rosenblatt：上调Innoviz Technologies(INVZ)评级至"买入"，目标价从3.25美元升至4美元</p> <p>• B. Riley证券：上调Cognition Therapeutics(CGTX)评级至"买入"，目标价从1美元升至1.5美元</p> <p>• 富国银行：维持Ultragenyx制药(RARE)"超配"评级，目标价从75美元升至88美元</p> <p>• Maxim Group：首予Tru
2024-12-23 09:29
